|
1.
|
|
9 p, 267.2 KB |
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis : results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP)
/
Reich, Kristian (SCIderm GmbH) ;
Zschocke, I. (SCIderm GmbH) ;
Bachelez, Hervé (AP-HP Hôpital Saint-Louis) ;
de Jong, E.M.G.J. (Radboud University Medical Centre and Radboud University) ;
Gisondi, Paolo (University of Verona) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Warren, R. B. (Manchester Academic Health Science Centre) ;
Ortland, C. (Das Forschungsdock Service for Clinical Development) ;
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ;
Universitat Autònoma de Barcelona
Around two-thirds of patients with psoriasis do not adhere to topical treatment. The Topical Treatment Optimization Programme (TTOP), a five-element tool, includes guidance for the conversation between dermatologists/nurses and patients, patient information material, telephone/e-mail helpdesks and treatment reminders. [...]
2017 -  10.1111/bjd.15466
British journal of dermatology, Vol. 177 Núm. 1 (july 2017) , p. 197-205
|
|
|
2.
|
|
9 p, 1.1 MB |
The biological basis of disease recurrence in psoriasis : a historical perspective and current models
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Costanzo, Antonio (Humanitas University) ;
Muñoz-Elías, Ernesto J. (Janssen Research & Development) ;
Jazra, Maria (Medical Affairs) ;
Wegner, Sven (Janssen-Cilag GmbH) ;
Paul, Carle (Hôpital Larrey) ;
Conrad, Curdin (University Hospital CHUV) ;
Universitat Autònoma de Barcelona
A key challenge in psoriasis therapy is the tendency for lesions to recur in previously affected anatomical locations after treatment discontinuation following lesion resolution. Available evidence supports the concept of a localized immunological 'memory' that persists in resolved skin after complete disappearance of visible inflammation, as well as the role of a specific subpopulation of T cells characterized by the dermotropic CCR4 phenotype and forming a local memory. [...]
2022 - 10.1111/bjd.20963
British journal of dermatology, Vol. 186 Núm. 5 (may 2022) , p. 773-781
|
|
|
3.
|
|
11 p, 5.0 MB |
Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses
/
Chacón-Solano, Esteban (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
León Canseco, Carlos (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Díaz, F. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
García-García, Francisco (Centro de Investigación Príncipe Felipe (CIPF)) ;
García, M. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Escámez Toledano, María José (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Guerrero-Aspizua, Sara (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Conti, C.J. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Mencía, None (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Martínez-Santamaría, L. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Llames, S. (Tissue Engineering Unit. Centro Comunitario Sangre y Tejidos (CCST)) ;
Pévida, M. (Tissue Engineering Unit. Centro Comunitario Sangre y Tejidos (CCST)) ;
Carbonell-Caballero, J. (Centro de Investigación Príncipe Felipe (CIPF)) ;
Puig-Butille, Joan Anton (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Maseda, R. (La Paz Hospital) ;
Puig, Susana (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
de Lucas, R. (La Paz Hospital) ;
Baselga Torres, Eulàlia (Institut d'Investigació Biomèdica Sant Pau) ;
Larcher, F. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Dopazo, J. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
del Río, M. (Centro de Investigación Biomédica en Red de Enfermedades Raras)
Background: Recessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome (KS) and xeroderma pigmentosum complementation group C (XPC) are three cancer-prone genodermatoses whose causal genetic mutations cannot fully explain, on their own, the array of associated phenotypic manifestations. [...]
2019 - 10.1111/bjd.17698
British journal of dermatology, Vol. 181 Núm. 3 (january 2019) , p. 512-522
|
|
|
4.
|
|
|
5.
|
|
3 p, 1.3 MB |
Vaccine hesitancy and access to psoriasis care during the -19 pandemic : findings from a global patient-reported cross-sectional survey
/
Bechman, Katie (King's College London) ;
Cook, Emma S. (King's College London) ;
Dand, Nick (Health Data Research UK) ;
Yiu, Zenas Z.N. (The University of Manchester) ;
Tsakok, Teresa (King's College London) ;
Meynell, Freya (King's College London) ;
Coker, Bolaji (King's College London) ;
Vincent, Alexandra (King's College London) ;
Bachelez, Hervé (Université de Paris) ;
Barbosa, Ines (King's College London) ;
Brown, Matthew A. (King's College London) ;
Capon, Francesca (King's College London) ;
Contreras, Claudia R. (Universidad Nacional de Asuncion) ;
De La Cruz, Claudia (Clinica Dermacross) ;
Di Meglio, Paola (King's College London) ;
Gisondi, Paolo (University of Verona) ;
Jullien, Denis (Groupe de recherche sur le psoriasis (GrPso) de la Société Française de dermatologie) ;
Kelly, Jade (NIHR Manchester Biomedical Research Centre) ;
Lambert, Jo (Ghent University) ;
Lancelot, Camille (International Federation of Psoriasis Associations) ;
Langan, Sinead M. (London School of Hygiene and Tropical Medicine) ;
Mason, Kayleigh J. (Keele University) ;
McAteer, Helen (The Psoriasis Association) ;
Moorhead, Lucy (King's College London) ;
Naldi, Luigi (Centro Studi GISED) ;
Norton, Sam (King's College London) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Spuls, Phyllis I. (Amsterdam UMC. University Medical Center) ;
Torres, Tiago (Centro Hospitalar do Porto) ;
Urmston, Dominic (The Psoriasis Association) ;
Vesty, Amber (The Psoriasis Association) ;
Warren, Richard B. (NIHR Manchester Biomedical Research Centre) ;
Waweru, Hoseah (International Federation of Psoriasis Associations) ;
Weinman, John (King's College London) ;
Griffiths, Christopher E.M. (NIHR Manchester Biomedical Research Centre) ;
Barker, Jonathan (King's College London) ;
Smith, Catherine H. (King's College London) ;
Galloway, James B. (King's College London) ;
Mahil, Satveer K. (King's College London) ;
Universitat Autònoma de Barcelona
2022 - 10.1111/bjd.21042
British journal of dermatology, Vol. 187 (may 2022) , p. 254-256
|
|
|
6.
|
|
11 p, 652.6 KB |
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type : a cross-sectional patient survey*
/
Mahil, Satveer K. ;
Yates, Mark (King's College London) ;
Langan, Sinead M. (London School of Hygiene and Tropical Medicine) ;
Yiu, Zenas Z.N. ;
Tsakok, Teresa ;
Dand, Nick ;
Mason, Kayleigh J. ;
McAteer, Helen ;
Meynell, Freya ;
Coker, Bolaji ;
Vincent, A. (Guy's and St Thomas' NHS Foundation Trust) ;
Urmston, Dominic ;
Vesty, Amber ;
Kelly, J. (The University of Manchester) ;
Lancelot, Camille (France Veterinary International) ;
Moorhead, Lucy (Guy's and St Thomas' NHS Foundation Trust) ;
Bachelez, Hervé (Université Paris Cité) ;
Bruce, I.N. (The University of Manchester) ;
Capon, Francesca (King's College London) ;
Contreras, Claudia Romina (Universidad Nacional de Asunción) ;
Cope, Andrew P. (Kingston College United Kingdom) ;
De La Cruz, C. (University of Santiago, Chile) ;
Di Meglio, Paola (Newcastle University) ;
Gisondi, Paolo (University of Verona) ;
Hyrich, Kimme (The University of Manchester) ;
Jullien, Denis (Hospices Civils de Lyon (Centre Hospitalier Universitaire de Lyon)) ;
Lambert, Julien ;
Marzo-Ortega, H. (Leeds Teaching Hospitals NHS Trust) ;
McInnes, Iain B. (University of Glasgow) ;
Naldi, L. (San Bortolo Hospital) ;
Norton, Sam (King's College London) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Sengupta, Raj (Royal National Hospital For Rheumatic Diseases NHS Foundation Trust) ;
Spuls, Phyllis (University of Amsterdam) ;
Torres, Tiago (Centro Hospitalar e Universitário do Porto) ;
Warren, Richard B. (The University of Manchester) ;
Waweru, Hoseah (Upper Hill Medical Centre) ;
Weinman, John (King's College London) ;
Griffiths, Chris E.M. (The University of Manchester) ;
Barker, Jonathan (The Kings College) ;
Brown, Matthew A. (Guy's and St Thomas' NHS Foundation Trust) ;
Galloway, James B. ;
Smith, Catherine (King's College London)
Background: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments. [...]
2021 - 10.1111/bjd.19755
British journal of dermatology, Vol. 185 Núm. 1 (july 2021) , p. 80-90
|
|
|
7.
|
|
11 p, 1.5 MB |
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis : interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up
/
Papp, Kim A (K Papp Clinical Research and Probity Medical Research) ;
Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Ohtsuki, M. (Jichi Medical University) ;
Beissert, Stefan (Department of Dermatology. University Hospital Carl Gustav Carus. TU Dresden) ;
Zeng, J. (AbbVie Inc.) ;
Rubant, S. (AbbVie Inc.) ;
Sinvhal, R. (AbbVie Inc.) ;
Zhao, Y. (AbbVie Inc.) ;
Soliman, A.M. (AbbVie Inc.) ;
Alperovich, G. (AbbVie Inc.) ;
Leonardi, C. (Central Dermatology. Richmond Heights)
Background: Psoriasis is a chronic inflammatory skin disease requiring prolonged treatment. New biologic therapies require long-term evaluation to assess the durability of their efficacy and safety profiles over time. [...]
2021 - 10.1111/bjd.20595
British journal of dermatology, Vol. 185 Núm. 6 (december 2021) , p. 1135-1145
|
|
|
8.
|
|
3 p, 147.0 KB |
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab
/
Brunner, Patrik M. (Medical University of Vienna) ;
Conrad, Curdin (Lausanne University Hospital) ;
Vender, Ronald (Dermatrials Research Inc) ;
Grond, Susanne (Eli Lilly and Company, Indianapolis) ;
Schuster, Christopher F. (Eli Lilly and Company, Indianapolis) ;
Patel, Hanna (Eli Lilly and Company, Indianapolis) ;
Xu, Wen (Eli Lilly and Company, Indianapolis) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
2021 - 10.1111/bjd.20527
British journal of dermatology, Vol. 185 (august 2021) , p. 865-867
|
|
|
9.
|
|
8 p, 883.0 KB |
Estimating personal solar ultraviolet radiation exposure through time spent outdoors, ambient levels and modelling approaches
/
Soueid, Lara (Institut de Salut Global de Barcelona) ;
Triguero-Mas, Margarita (Universitat Autònoma de Barcelona. Institut de Ciència i Tecnologia Ambientals) ;
Dalmau, A. (Institut de Salut Global de Barcelona) ;
Barrera-Gómez, José (Institut de Salut Global de Barcelona) ;
Alonso García, Lucía (Institut de Salut Global de Barcelona) ;
Basagaña, X (Institut de Salut Global de Barcelona) ;
Thieden, E. (Bispebjerg Hospital) ;
Wulf, H. C. (Bispebjerg Hospital) ;
Diffey, B. (Newcastle University) ;
Young, A. R. (King's College London) ;
Nieuwenhuijsen, Mark (Institut de Salut Global de Barcelona) ;
Dadvand, Payam (Institut de Salut Global de Barcelona)
Background: Evidence on validation of surrogates applied to evaluate the personal exposure levels of solar ultraviolet radiation (UVR) in epidemiological studies is scarce. Objectives: To determine and compare the validity of three approaches, including (i) ambient UVR levels, (ii) time spent outdoors and (iii) a modelling approach integrating the aforementioned parameters, to estimate personal UVR exposure over a period of 6 months among indoor and outdoor workers and in different seasons (summer/winter). [...]
2021 - 10.1111/bjd.20703
British journal of dermatology, 2021
|
|
|
10.
|
|
13 p, 3.0 MB |
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase clinical trials (re 1 and re 2) through 148 weeks
/
Reich, Kristian (Dermatologikum Berlin) ;
Warren, R. B. (The University of Manchester. Manchester NIHR Biomedical Research Centre. Salford Royal NHS Foundation Trust) ;
Iversen, Lars (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ;
Pau-Charles, I. (Almirall R&D) ;
Igarashi, A. (NTT Medical Center Tokyo) ;
Ohtsuki, M. (Jichi Medical University) ;
Falqués, M. (Almirall R&D) ;
Harmut, M. (Almirall R&D) ;
Rozzo, S. (Sun Pharmaceuticals) ;
Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ;
Cantrell, W. (University of Alabama at Birmingham) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Thaçi, Diamant (University of Lübeck) ;
Universitat Autònoma de Barcelona
Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe psoriasis for up to 148 weeks. [...]
2019 - 10.1111/bjd.18232
British journal of dermatology, Vol. 182 (july 2019) , p. 605-617
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
